Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623723 | 0.84 | SIGMAR1 (0.47) | SIGMAR1SCN4ACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL13623727 | 0.84 | SIGMAR1 (0.44) | SIGMAR1SCN4ACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL13623724 | 0.83 | SIGMAR1 (0.43) | SIGMAR1SCN4ACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL15342270 | 0.81 | SLC6A4 (0.55) | — | |
| SCHEMBL9765336 | 0.81 | SLC6A4 (0.55) | — | |
| Hydrochloric Acid SCHEMBL11209663 | 0.80 | SLC6A4 (0.53) | — | |
| SCHEMBL28758239 | 0.79 | LDHA (0.50) | SIGMAR1ALOX15ALOX12 | |
| SCHEMBL14040059 | 0.79 | ANPEP (0.41) | ANPEPSIGMAR1ENPEPALOX15ALOX12 | |
| SCHEMBL14039993 | 0.79 | ANPEP (0.41) | ANPEPSIGMAR1ENPEPALOX15ALOX12 | |
| SCHEMBL20386033 | 0.79 | ALOX15 (0.50) | CRHBPCRHR2SMN1; SMN2ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619116-B2 | Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | Products Chimiques Auxiliaires Et de Synthese (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | ANPEP 724/4885SIGMAR1 959/4885SCN4A 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.